The stock market extended its losing streak as escalating geopolitical tensions and rising bond yields drove the Dow Jones Industrial Average down 419 points, marking a turbulent start to what historically is the most challenging month for equities. With crude oil prices surging above $90 per barrel following attacks on tankers in the Strait of Hormuz and fresh U.S. strikes against Iran, investor sentiment turned decisively risk-averse. This comprehensive market analysis examines the key drivers behind Tuesday’s selloff, including the surge in global bond yields, shifting Federal Reserve expectations, sector rotation patterns, and notable individual stock movements that shaped the trading session.
Geopolitical Tensions and Rising Oil Prices Weigh on Sentiment
The front-month West Texas Intermediate crude oil futures contract rose another 5.7% to $90.64 per barrel after a private maritime security firm, Marisks, reported attacks on two tankers transiting the Strait of Hormuz on Monday. The U.S. launched new strikes against Iran on Tuesday, further intensifying the conflict in the Middle East. More war on top of more government spending on top of more borrowed capex for the AI boom means more inflation everywhere, at least according to expectations reflected in global bond yields. This combination of geopolitical risk, fiscal expansion, and capital-intensive technology investment has created a perfect storm for inflation expectations, directly impacting both fixed income and equity markets.
The broad-based S&P 500 shed 0.7% to 7,631, while the tech-heavy Nasdaq Composite was lower by 1.03% at 26,099. Energy stocks, including Chevron (CVX, +2.4%) with its new deal to exploit Venezuelan oil reserves, led to the upside. Consumer staples stocks, including Procter & Gamble (PG, +0.8%), and healthcare names such as UnitedHealth Group (UNH, +1.8%) also benefited from a rotation into traditional “risk-off” sectors. Utility stocks were up, too.
Global Bond Yields Surge to Multi-Decade Highs
Yield on the 10-year Japanese government bond broke above 3% for the first time since 1996, and the 30-year U.K. government bond yield hit its highest level since 1998. Meanwhile, the yield on the 2-year Treasury hit a new 52-week intraday high of 4.400% and closed up 4.8 basis points to 4.398%. The 10-year Treasury yield (+3.4 bps, 4.792%) and the 30-year Treasury yield (+1.7 bps, 5.266%) were up again, too.
Fed Rate Hike Probability Reverses Course
A month ago, the probability of a rate hike at the conclusion of the September 15-16 Federal Open Market Committee (FOMC) meeting was 67.0%. A week ago, according to CME FedWatch, it was 39.6%. Today, with upward pressure on prices rising again, the odds of a 25-basis-point increase in the federal funds rate are back up to 68.2%. This dramatic shift in expectations underscores how quickly the macroeconomic narrative has changed from disinflation optimism to renewed inflation concerns driven by energy costs and fiscal stimulus.
It is “risk off” right now, and the bond market is sending a clear signal that the era of low yields and easy monetary policy is firmly in the rearview mirror. For equity investors, this means valuation multiples face continued compression, particularly for growth-oriented sectors that benefit most from lower discount rates.
Defensive Sector Rotation Intensifies as Growth Stocks Falter
The market’s defensive pivot was on full display Tuesday. Energy stocks surged on the back of higher crude prices, with Chevron’s Venezuelan oil deal providing an additional catalyst. Consumer staples and healthcare names also outperformed as investors sought safety in sectors with predictable earnings and stable demand. Apple (AAPL, +2.6%) was the best-performing Dow Jones stock during its first trading session under new leadership.
Apple’s New Chapter Under John Ternus
If new CEO John Ternus does what old CEO Tim Cook did in terms of market cap multiplication, AAPL will be worth well north of $60 trillion by the time he steps aside in a decade and a half or so. Apple’s market cap at today’s close was $4.75 trillion. The stock’s resilience amid a broad market decline highlights the confidence investors have in the company’s product pipeline, services revenue growth, and capital allocation strategy. The leadership transition appears smooth, with the market rewarding stability and continuity.
Palo Alto Networks Faces Earnings Test After Monumental Rally
Palo Alto Networks (PANW, -5.2%), a cybersecurity stock with an AI twist good enough to send it more than 100% higher since early May, retraced some of that move ahead of its turn on the earnings calendar after today’s close. Wall Street expects PANW management to report earnings of 98 cents per share, up from 95 cents a year ago, on revenue growth of more than 33% to $3.35 billion.
Stifel analyst Adam Borg reiterated his Buy rating on the tech stock and raised his 12-month target price from $330 to $415 in a mid-August earnings preview. Borg noted that PANW was a “crowded long” with “a rich multiple and elevated expectations.” At the same time, citing recent vendor checks that continue to support its “strong positioning,” the analyst believes “any near-term weakness, should there be any, gets bought.”
The cybersecurity sector remains a high-conviction area for institutional investors given the secular tailwinds from digital transformation, cloud adoption, and the proliferation of AI-driven threats. However, elevated expectations mean even slight disappointments can trigger sharp corrections in names like PANW that have already priced in significant future growth.
Novartis Surges on Multiple Sclerosis Drug Breakthrough
Novartis (NVS, +6.0%), a large-cap stock whose American Depositary Receipts (ADRs) trade on the New York Stock Exchange (NYSE), had barely outperformed the S&P 500 year to date through Monday. But the Switzerland-based drugmaker got a big boost Tuesday after management announced positive Phase III trial results for a pill to treat multiple sclerosis (MS).
According to Novartis, “Remibrutinib, a highly selective and potent oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile.” That is good news for people with MS and those who care about them. The potential blockbuster drug could significantly alter the treatment landscape for relapsing multiple sclerosis, a market currently dominated by injectable and infusion therapies. We will see whether the data sways Wall Street analysts. Five rate NVS a Buy, but four say it is a Hold and three say it is a Sell. That is good for a consensus “Hold” rating, according to S&P Global Market Intelligence.
The biopharmaceutical sector continues to demonstrate that significant value creation comes from pipeline execution rather than broad market direction. Novartis’ strong move in a down market illustrates how company-specific catalysts can overcome macro headwinds, particularly when the catalyst addresses a large unmet medical need.
Tuesday’s market action serves as a powerful reminder that the interplay between geopolitics, monetary policy, and inflation expectations remains the dominant force driving asset allocation decisions. While bond yields have historically provided a tug-of-war with equity valuations, the current environment challenges investors to navigate a landscape where defensive positioning, commodity exposure, and selective growth stocks each play distinct roles in portfolio construction. As the probability of a September rate hike climbs back above two-thirds and geopolitical risks show no signs of abating, market participants would be wise to prioritize diversification, focus on quality earnings, and remain nimble in response to both macroeconomic data and individual company developments.
